WHO ICTRP trial
A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY…
EUCTR2010-021789-31-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2010-021789-31-DE |
|---|---|
| Public title | A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIOUSLY TAKEN VARENICLINE |
| Scientific title | A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIOUSLY TAKEN VARENICLINE |
| Primary sponsor | Pfizer Inc.235 East 42nd Street, New York, NY 10017 US |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Czech Republic;Germany;United Kingdom |
| Conditions | Smoking Cessation MedDRA version: 15.0 Level: PT Classification code 10053325 Term: Smoking cessation therapy System Organ Class: 10042613 - Surgical and medical procedures |
| Interventions | Trade Name: CHAMPIX Pharmaceutical Form: Film-coated tablet CAS Number: 375815-87-5 Other descriptive name: VARENICLINE TARTRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of… |
| Registration date | Feb 9, 2010 |
| Target size | 490 |
| Secondary IDs | A3051139 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: